Gilead Sciences: Toward Health Equity for Black People Impacted by TNBC
Originally Published by Gilead Sciences
Racism and the impact of social determinants of health drive disparities in outcomes for Black women impacted by triple-negative breast cancer (TNBC). Addressing these barriers is critical to advancing health equity.
Gilead awarded $5.7M in grants to 21 U.S. organizations for programs working to advance health equity for Black people impacted by TNBC.
Two grants are focused on organizational capacity building for Black-led organizations to help enhance their reach and sustainability.
Programmatic grants are focused on supporting local, regional and national approaches to bridging gaps across the cancer care continuum by:
- Addressing the role of social determinants of health in access across the care continuum
- Creating sustainable solutions to promoting racial equity in breast cancer care
- Improving community, patient and provider communication, and relationships and engagement throughout the care continuum
- Providing outreach and education about TNBC for communities, patients, families and caregivers
- Supplying resources to help people navigate the TNBC healthcare journey
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
